Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
作者信息
Rasi Silvia, Khiabanian Hossein, Ciardullo Carmela, Terzi-di-Bergamo Lodovico, Monti Sara, Spina Valeria, Bruscaggin Alessio, Cerri Michaela, Deambrogi Clara, Martuscelli Lavinia, Biasi Alessandra, Spaccarotella Elisa, De Paoli Lorenzo, Gattei Valter, Foà Robin, Rabadan Raul, Gaidano Gianluca, Rossi Davide
机构信息
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Center for Topology of Cancer Evolution and Heterogeneity, Department of Biomedical Informatics and Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA.
出版信息
Haematologica. 2016 Apr;101(4):e135-8. doi: 10.3324/haematol.2015.136051. Epub 2016 Jan 27.
Abstract
摘要
相似文献
1
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica. 2016 Apr;101(4):e135-8. doi: 10.3324/haematol.2015.136051. Epub 2016 Jan 27.
2
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Leuk Lymphoma. 2014 Dec;55(12):2785-92. doi: 10.3109/10428194.2014.898760.
3
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.
4
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Oncotarget. 2015 Mar 10;6(7):5426-34. doi: 10.18632/oncotarget.3101.
5
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Leukemia. 2013 Nov;27(11):2196-9. doi: 10.1038/leu.2013.98. Epub 2013 Apr 5.
6
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Haematologica. 2015 Mar;100(3):370-6. doi: 10.3324/haematol.2014.109777. Epub 2014 Dec 5.
7
Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):271-6. doi: 10.1016/j.clml.2013.12.016. Epub 2013 Dec 30.
8
THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Probl Radiac Med Radiobiol. 2018 Dec;23:283-301. doi: 10.33145/2304-8336-2018-23-283-301.
9
On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
Leukemia. 2014 Mar;28(3):710-3. doi: 10.1038/leu.2013.333. Epub 2013 Nov 12.
10
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.
引用本文的文献
1
Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1.
Cancer Cell Int. 2025 Mar 19;25(1):104. doi: 10.1186/s12935-025-03702-4.
2
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.
Cancers (Basel). 2024 Oct 14;16(20):3483. doi: 10.3390/cancers16203483.
3
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.
Pharmaceutics. 2023 Dec 29;16(1):55. doi: 10.3390/pharmaceutics16010055.
4
Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
Leuk Res. 2022 May;116:106827. doi: 10.1016/j.leukres.2022.106827. Epub 2022 Mar 21.
5
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.
Diagnostics (Basel). 2021 May 10;11(5):853. doi: 10.3390/diagnostics11050853.
6
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.
Haematologica. 2022 Mar 1;107(3):604-614. doi: 10.3324/haematol.2020.265777.
7
Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression.
J Clin Med. 2020 Nov 17;9(11):3695. doi: 10.3390/jcm9113695.
8
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study.
Haematologica. 2021 Mar 1;106(3):682-691. doi: 10.3324/haematol.2019.234716.
9
Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
PLoS One. 2019 Jul 23;14(7):e0220177. doi: 10.1371/journal.pone.0220177. eCollection 2019.
10
mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients.
Ann Transl Med. 2019 Apr;7(8):176. doi: 10.21037/atm.2019.03.63.
本文引用的文献
1
Mutations driving CLL and their evolution in progression and relapse.
Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14.
2
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.
Elife. 2014 Dec 11;3:e02869. doi: 10.7554/eLife.02869.
3
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Blood. 2014 Apr 3;123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5.
4
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
Br J Haematol. 2013 Nov;163(4):496-500. doi: 10.1111/bjh.12539. Epub 2013 Aug 27.
5
Clinical implications of the molecular genetics of chronic lymphocytic leukemia.
Haematologica. 2013 May;98(5):675-85. doi: 10.3324/haematol.2012.069369.
6
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Clin Cancer Res. 2013 Jun 1;19(11):2893-904. doi: 10.1158/1078-0432.CCR-13-0138. Epub 2013 Apr 25.
7
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Cell. 2013 Feb 14;152(4):714-26. doi: 10.1016/j.cell.2013.01.019.
8
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.
Blood. 2012 Nov 15;120(20):4191-6. doi: 10.1182/blood-2012-05-433540. Epub 2012 Aug 22.
9
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Blood. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3.
Zotero 插件